Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Sep 16, 2026 → Sep 16, 2027
See other at-risk trials from Jonsson Comprehensive Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 16, 2026 to Sep 16, 2027
    • Study completion pushed from Sep 16, 2027 to Sep 16, 2028
    • Eligibility criteria expanded, about 4 words
  2. Primary completion date: Sep 16, 2025 to Sep 16, 2026
    • Study completion date: Sep 16, 2026 to Sep 16, 2027
    v14
  3. Primary completion date: Sep 16, 2024 to Sep 16, 2025
    • Study completion date: Sep 16, 2025 to Sep 16, 2026
    v13
  4. 4 versions Re-verified since Jul 28, 2021, no change to tracked fieldsv9-v12
  5. Collaborators shortened, about 4 wordsv8
Show 6 earlier versionsHide 6 earlier versions
  1. 2 versions Re-verified since Feb 26, 2019, no change to tracked fieldsv6-v7
  2. Primary completion date: Nov 2024 to Sep 16, 2024
    • Study completion date: Nov 2025 to Sep 16, 2025
    • Start date: Sep 2014 to Sep 16, 2014
    v5
  3. 3 versions Re-verified since Sep 3, 2015, no change to tracked fieldsv2-v4
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research trial studies germ-line mutations in blood and saliva samples from patients with cancer. Studying samples of blood and saliva from patients with cancer in the laboratory may help doctors learn more about how inherited genetic mutations can affect cancer predisposition (an inherited increase in the risk of developing cancer), their impact on treatment response, and their role in cancer development.
Trial Details
NCT Number NCT02280161
Lead Sponsor Jonsson Comprehensive Cancer Center
Conditions
(from sponsor)		 Malignant Neoplasm
Related terms Neoplasms
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov